CompanyGraph
At a glance
- Depends onMidstream position: 5 outgoing, 4 incoming connections
- FinancialsAltman Z-Score 3.85: safe zone
Sign in to view price data.
Sign inThe reported statements, read against the company's own industry.
Financials view
Market Capitalization
7.21BCNY1.07B · vs all stocks (USD)
Revenue (TTM)
590.13MCNY87.76M · vs all stocks (USD)
Profit Margin
-45.26%Beta
0.0180xvs all stocks
52-Week Change
-29.92%vs all stocks
Market Capitalization
7.21BCNY1.07B · vs all stocks (USD)
Enterprise Value
6.57BCNY977.31M · vs all stocks (USD)
Forward P/E
-581.33xPrice to Sales (TTM)
10.93xPrice to Book (MRQ)
1.68xEnterprise to Revenue
11.14xEnterprise to EBITDA
-40.02xGross Margin
80.95%Profit Margin
-45.26%Return on Assets (TTM)
-3.60%Return on Equity (TTM)
-6.63%Revenue (TTM)
590.13MCNY87.76M · vs all stocks (USD)
Revenue per Share (TTM)
1.43CNYUpdated Aug 21, 2026Quarterly Revenue Growth
-9.20%Gross Profit (TTM)
373.09MCNY55.48M · vs all stocks (USD)
EBITDA (TTM)
-164.21MCNY-24.42M · vs all stocks (USD)
Net Income (TTM)
-267.12MCNY-39.72M · vs all stocks (USD)
Operating Cash Flow (TTM)
318.70MCNY47.39M · vs all stocks (USD)
Levered Free Cash Flow (TTM)
-153.00MCNY-22.75M · vs all stocks (USD)
Payout Ratio
338.00%Revenue
605.07MCNYFY2025 · Dec 31, 2025Cost of Goods Sold
160.74MCNYFY2025 · Dec 31, 2025Gross Profit
444.34MCNYFY2025 · Dec 31, 2025Operating Income
-216.64MCNY-32.22M · vs all stocks (USD)
Pre-tax Income
-331.90MCNYFY2025 · Dec 31, 2025Income Tax Expense
-69.32MCNYFY2025 · Dec 31, 2025Net Income
-262.58MCNYFY2025 · Dec 31, 2025EBIT
-328.00MCNYFY2025 · Dec 31, 2025EBITDA (Income Statement)
-116.61MCNYFY2025 · Dec 31, 2025Research & Development
177.10MCNYFY2025 · Dec 31, 2025Selling, General & Administrative
380.45MCNYFY2025 · Dec 31, 2025Other Operating Expenses
15.40MCNYFY2025 · Dec 31, 2025Non-operating Interest Income
3.07MCNYFY2025 · Dec 31, 2025Non-operating Interest Expense
3.90MCNYFY2025 · Dec 31, 2025EPS (Basic)
-0.6400CNYFY2025 · Dec 31, 2025EPS (Diluted)
-0.6400CNYFY2025 · Dec 31, 2025Basic Shares Outstanding
410.28MSharesFY2025 · Dec 31, 2025Diluted Shares Outstanding
410.28MSharesFY2025 · Dec 31, 2025Net Income from Continuing Operations
-262.58MCNYFY2025 · Dec 31, 2025Preferred Stock Dividends
0.00CNYFY2025 · Dec 31, 2025Operating Cash Flow
96.39MCNYFY2025 · Dec 31, 2025Free Cash Flow
-310.03MCNYFY2025 · Dec 31, 2025Cash & Cash Equivalents (End of Period)
201.24MCNYFY2025 · Dec 31, 2025Starting Profit (CF Statement)
-262.58MCNYFY2025 · Dec 31, 2025Other Non-cash Items
22.92MCNYFY2025 · Dec 31, 2025Change in Accounts Receivable (CF)
466.31MCNYFY2025 · Dec 31, 2025Change in Other Assets/Liabilities
-130.26MCNYFY2025 · Dec 31, 2025Capital Expenditures
-406.42MCNYFY2025 · Dec 31, 2025Purchase of Investments
-50.00MCNYFY2025 · Dec 31, 2025Net Investing Cash Flow
-456.42MCNYFY2025 · Dec 31, 2025Long-term Debt Issuance
334.65MCNYFY2025 · Dec 31, 2025Long-term Debt Payments
-172.24MCNYFY2025 · Dec 31, 2025Common Dividends Paid
-75.03MCNYFY2025 · Dec 31, 2025Net Financing Cash Flow
87.38MCNYFY2025 · Dec 31, 2025Shares Outstanding
413.66MSharesUpdated Aug 21, 2026Float Shares
119.67MSharesUpdated Aug 21, 2026% Held by Insiders
72.54%vs all stocks
% Held by Institutions
0.86%vs all stocks
Total Cash (MRQ)
215.47MCNY32.04M · vs all stocks (USD)
Total Cash per Share (MRQ)
0.5210CNYUpdated Aug 21, 2026Total Debt (MRQ)
338.45MCNY50.33M · vs all stocks (USD)
Total Debt to Equity (MRQ)
0.0880xCurrent Ratio (MRQ)
1.28xBook Value per Share (MRQ)
9.30CNYUpdated Aug 21, 2026Total Assets
5.07BCNY753.72M · vs all stocks (USD)
Total Current Assets
1.42BCNYFY2025 · Dec 31, 2025Total Liabilities
1.22BCNYFY2025 · Dec 31, 2025Total Non-current Assets
3.65BCNYFY2025 · Dec 31, 2025Total Non-current Liabilities
112.63MCNYFY2025 · Dec 31, 2025Total Current Liabilities
1.10BCNYFY2025 · Dec 31, 2025Cash
201.24MCNYFY2025 · Dec 31, 2025Cash Equivalents
0.00CNYFY2025 · Dec 31, 2025Cash & Cash Equivalents
201.24MCNYFY2025 · Dec 31, 2025Accounts Receivable
936.82MCNYFY2025 · Dec 31, 2025Inventory
226.55MCNYFY2025 · Dec 31, 2025Accounts Payable
19.60MCNYFY2025 · Dec 31, 2025Short-term Debt
201.65MCNYFY2025 · Dec 31, 2025Other Current Liabilities
42.31MCNYFY2025 · Dec 31, 2025Long-term Debt
63.58MCNYFY2025 · Dec 31, 2025Other Non-current Liabilities
2.28KCNYFY2025 · Dec 31, 2025Common Stock (Book)
413.66MCNYFY2025 · Dec 31, 2025Retained Earnings
1.12BCNYFY2025 · Dec 31, 2025Total Shareholders' Equity
3.85BCNY572.67M · vs all stocks (USD)
52-Week Low
13.30CNYUpdated Aug 21, 202652-Week High
25.72CNYUpdated Aug 21, 202652-Week Change
-29.92%vs all stocks
Beta
0.0180xvs all stocks
50-Day MA
14.74CNYUpdated Aug 21, 2026200-Day MA
18.04CNYUpdated Aug 21, 2026Avg 10-Day Volume
2.34MSharesUpdated Aug 21, 2026Avg 30-Day Volume
2.27MSharesUpdated Aug 21, 2026Diluted EPS (TTM)
-0.6500CNYUpdated Aug 21, 2026Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Structural Tensions
High gross margins eroded by operating costsNotable
Gross Margin: 0.81Profit Margin: -0.45
Financial Health
Altman Z-Score 3.85: safe zoneNotable
Altman Z-Score: 3.85
Supply Chain
Midstream position: 5 outgoing, 4 incoming connectionsNotable
Outgoing: 5.00Incoming: 4.00
Companies that share the same coordination system — how they create, deliver, or capture value.
Dezhan Health Care Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Lifetech Scientific Corporation
Tier 1ProductionApproval-Gated PipelineRule
Anhui Wanbang Pharmaceutical Co. Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Akums Drugs & Pharmaceuticals Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Jiangsu Kanion Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Kuros Biosciences AG
Tier 1ProductionApproval-Gated PipelineRuleSenseMaking
Blue Jet Healthcare Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Alto Neuroscience Inc.
Tier 1ProductionApproval-Gated PipelineRuleSenseMaking
Lexicon Pharmaceuticals, Inc.
Tier 1ProductionApproval-Gated PipelineRule
Eis Eczacıbaşı İlaç ve Sanayi A.Ş.
Tier 1ProductionApproval-Gated PipelineRuleFlow